Obesity & Metabolic Weight Management

About This Condition

Obesity is a chronic, relapsing neuroendocrine disease — not a failure of willpower. It is driven by complex interactions between genetics, hormonal signaling (leptin resistance, insulin resistance, ghrelin dysregulation), gut microbiome composition, sleep, stress physiology, and environmental factors. Despite this, most medical care offers little beyond "eat less, move more" and, increasingly, a prescription for a GLP-1 agonist without a surrounding metabolic framework. The result is patients who lose weight initially but regain it, often with higher body fat percentage and reduced lean muscle mass — a phenomenon called sarcopenic obesity.

Our Approach

We use iDXA body composition scanning to establish baseline lean mass, fat mass, visceral fat area, and segmental distribution — and we track these independently of scale weight. Our metabolic evaluation includes fasting insulin, HOMA-IR, leptin, adiponectin, sex hormones (testosterone, SHBG, estradiol), and thyroid function. Treatment is individualized and may include compounded GLP-1-based pharmacotherapy (semaglutide, tirzepatide), structured therapeutic nutrition protocols designed to preserve lean mass, progressive resistance training prescriptions, and sleep optimization (given the direct link between sleep disruption and appetite dysregulation). We monitor body composition quarterly — ensuring fat loss without muscle loss — and adjust protocols based on metabolic response. This is precision weight management, not a prescription handoff.